Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, UK.
Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Chapeltown Rd, Leeds, LS7 4SA, UK.
Calcif Tissue Int. 2021 Sep;109(3):339-350. doi: 10.1007/s00223-020-00672-9. Epub 2020 Feb 13.
Osteoarthritis (OA) is a chronic, debilitating disease affecting millions of people worldwide. Management of OA involves pharmacological and non-pharmacological approaches. Conventional pharmacological treatments have limited efficacy and are associated with a number of side-effects, restricting the number of patients who can use them. New pharmacological therapies for managing OA are required and a number have been developed targeting different tissues in OA: bone and cartilage, synovium and nerves. However, there has been overall limited success. Disease-modifying osteoarthritis drugs (DMOADs) are a putative class of therapies aimed at improving OA structural pathologies and consequent symptoms. Recent DMOAD studies have demonstrated some promising therapies but also provided new considerations for future trials.
骨关节炎（OA）是一种影响全球数百万人的慢性、使人虚弱的疾病。OA 的管理包括药物和非药物方法。传统的药物治疗效果有限，并且与许多副作用相关，限制了可以使用它们的患者数量。需要新的药物治疗方法来管理 OA，并且已经开发了许多针对 OA 不同组织的治疗方法：骨骼和软骨、滑膜和神经。然而，总体上成功有限。改善骨关节炎结构病理学和相应症状的潜在治疗方法。最近的 DMOAD 研究已经证明了一些有前途的治疗方法，但也为未来的试验提供了新的考虑因素。
